MAM
CPRX

Meeder Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Meeder Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,392
Closed -$257K – 962
2026
Q1 		$257K Buy
+10,392
New +$248K 0.01% 275
2025
Q3 		– Sell
-2,957
Closed -$64.2K – 836
2025
Q2 		$64.2K Sell
2,957
-6,484
-69% -$153K ﹤0.01% 342
2025
Q1 		$229K Sell
9,441
-2,392
-20% -$53.9K 0.02% 236
2024
Q4 		$247K Buy
11,833
+7,336
+163% +$158K 0.02% 205
2024
Q3 		$89.4K Hold
4,497
– – 0.01% 303
2024
Q2 		$69.7K Buy
+4,497
New +$70K ﹤0.01% 304
2023
Q1 		– Sell
-22
Closed -$409 – 659
2022
Q4 		$409 Sell
22
-75
-77% -$1.16K ﹤0.01% 755
2022
Q3 		$1K Buy
+97
New +$1.15K ﹤0.01% 1926
2021
Q4 		– Sell
-18,581
Closed -$99K – 1414
2021
Q3 		$99K Hold
18,581
– – 0.01% 897
2021
Q2 		$107K Hold
18,581
– – 0.01% 889
2021
Q1 		$85K Buy
+18,581
New +$73.8K ﹤0.01% 955
2020
Q4 		– Sell
-18,582
Closed -$55K – 1943
2020
Q3 		$55K Hold
18,582
– – ﹤0.01% 935
2020
Q2 		$86K Buy
18,582
+4,835
+35% +$21.7K 0.01% 792
2020
Q1 		$52K Buy
13,747
+7,255
+112% +$29.8K ﹤0.01% 891
2019
Q4 		$25K Buy
6,492
+3,100
+91% +$14.5K ﹤0.01% 1278
2019
Q3 		$19K Sell
3,392
-9,859
-74% -$52.5K ﹤0.01% 1329
2019
Q2 		$50K Buy
13,251
+11,548
+678% +$49.9K ﹤0.01% 954
2019
Q1 		$9K Sell
1,703
-32,534
-95% -$95.6K ﹤0.01% 1264
2018
Q4 		$67K Buy
34,237
+22,227
+185% +$63.6K 0.01% 742
2018
Q3 		$46K Sell
12,010
-4,502
-27% -$14.1K ﹤0.01% 799
2018
Q2 		$51.5K Buy
16,512
+14,200
+614% +$43.1K ﹤0.01% 749
2018
Q1 		$5K Buy
2,312
+1,286
+125% +$4.27K ﹤0.01% 1214
2017
Q4 		$3K Buy
+1,026
New +$3.39K ﹤0.01% 1420

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Meeder Asset Management's CPRX Position: Q2 2026 in Review

Meeder Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 10,392 shares — an estimated $257K sold.

Meeder Asset Management first reported a position in CPRX in Q4 2017 and held it in 23 quarters. The position peaked at $257K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Meeder Asset Management reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Meeder Asset Management sold 10,392 Catalyst Pharmaceutical shares in Q2 2026, an estimated $257K.
  • Meeder Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 23 quarters.
  • Meeder Asset Management's Catalyst Pharmaceutical position peaked at $257K in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.